9月8日，Ionis Pharmaceuticals盘中下跌7.76%，报54.08美元/股，成交额9699.92万美元。
消息面上，合作伙伴诺华于9月4日宣布，由Ionis发现并早期开发的pelacarsen在III期LpHORIZON心血管结局试验中未达主要终点——尽管该药显著降低了脂蛋白(a)水平，但未能转化为心血管事件风险的降低。值得注意的是，这已是Ionis近两个月内遭遇的第二次重大III期试验挫折，此前7月其与阿斯利康合作的eplontersen在ATTR-CM心脏转归试验中同样未达主要终点，当时股价曾单日暴跌逾20%。连续的管线失利对市场信心形成持续压制。
Ionis Pharmaceuticals是一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，管线横跨神经病学、心脏代谢疾病等领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.